Item 7.01 Regulation FD Disclosure.
On December 28, 2020, Cara Therapeutics, Inc. (the "Company") issued a press
release announcing the submission of the new drug application to the U.S. Food
and Drug Administration for KORSUVA™ Injection for the treatment of
moderate-to-severe pruritus in hemodialysis patients. The information furnished
under this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for
purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or
subject to the liabilities of that section. The information shall not be deemed
incorporated by reference into any other filing with the Securities and Exchange
Commission made by the Company, regardless of any general incorporation language
in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit
No. Description
99.1 Press release dated December 28, 2020
104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
© Edgar Online, source Glimpses